Companies researching Imbruvica (ibrutinib)
Imbruvica (ibrutinib) is a small‑molecule BTK inhibitor that blocks B‑cell receptor signaling, used to treat B‑cell malignancies such as chronic lymphocytic leukemia/small lymphocytic lymphoma with 17p deletion and Waldenström’s macroglobulinemia.
12
companies
List of companies that research Imbruvica (ibrutinib)
| Company | Country | Industry | Employees | Revenue | Technologies |
|---|---|---|---|---|---|
 United States | Pharmaceutical Manufacturing | 62k | $26B | Imbruvica (ibrutinib) | |
United States | Hospitals and Health Care | 138k | $94B | Imbruvica (ibrutinib) | |
 United Kingdom | Hospitals and Health Care | 5k | Imbruvica (ibrutinib) | ||
 Denmark | Hospitals and Health Care | 25k | $5.9M | Imbruvica (ibrutinib) |
Showing top companies out of 12 that research Imbruvica (ibrutinib). Get the full list on TheirStack.
Frequently asked questions